VYNE Therapeutics Inc. (VYNE)
NASDAQ: VYNE · Real-Time Price · USD
0.5668
0.00 (0.00%)
At close: Jan 16, 2026, 4:00 PM EST
0.5600
-0.0068 (-1.20%)
Pre-market: Jan 20, 2026, 7:30 AM EST
VYNE Therapeutics Employees
VYNE Therapeutics had 13 employees as of December 31, 2024. The number of employees increased by 3 or 30.00% compared to the previous year.
Employees
13
Change (1Y)
3
Growth (1Y)
30.00%
Revenue / Employee
$40,308
Profits / Employee
-$2,589,846
Market Cap
18.87M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 13 | 3 | 30.00% | 13 | 0 |
| Dec 31, 2023 | 10 | -2 | -16.67% | 10 | 0 |
| Dec 31, 2022 | 12 | -16 | -57.14% | 12 | 0 |
| Dec 31, 2021 | 28 | -78 | -73.58% | 28 | 0 |
| Dec 31, 2020 | 106 | 66 | 165.00% | 106 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
VYNE News
- 4 weeks ago - VYNE Therapeutics Inc. (VYNE) Yarrow Bioscience, Inc. - M&A Call Prepared Remarks Transcript - Seeking Alpha
- 4 weeks ago - VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement - GlobeNewsWire
- 2 months ago - VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update - GlobeNewsWire
- 5 months ago - VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update - GlobeNewsWire
- 6 months ago - VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo - GlobeNewsWire
- 7 months ago - VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202 - GlobeNewsWire
- 9 months ago - VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update - GlobeNewsWire
- 9 months ago - FDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On Hold - Benzinga